The earliest and most alarming signs of osteogenesis imperfecta (OI) are fractures that happen with little or no trauma — a baby breaking a bone during a diaper change, a toddler fracturing a femur from standing up, or an adult snapping a rib while coughing. But fractures are just the beginning. OI is a systemic collagen disorder, and it leaves fingerprints across nearly every organ system that relies on connective tissue: eyes, teeth, ears, joints, and spine.
If you’re searching for these signs because your child has unexplained fractures or you’ve noticed a bluish tint to their eyes, you’re right to dig deeper. OI affects roughly 1 in 15,000 to 20,000 births, and mild forms can go undiagnosed for years — sometimes decades. Here’s exactly what to look for, organized by how commonly each sign appears and which OI type it’s associated with.
The 8 Core Signs of Osteogenesis Imperfecta
Not every person with OI has every symptom. The presentation depends heavily on which of the 21+ recognized OI types a person has and the specific genetic mutation involved. That said, these are the signs clinicians screen for:
| Sign | What It Looks Like | Most Common In |
|---|---|---|
| Recurrent fractures | Fractures from minimal trauma or no identifiable cause; may begin in utero | All types (hallmark feature) |
| Blue or gray sclera | A bluish-gray tint to the whites of the eyes due to thin scleral collagen | Types I, III, IV |
| Dentinogenesis imperfecta | Translucent, discolored teeth that chip and wear prematurely | Types III, IV (about 50% of all OI patients) |
| Short stature | Height significantly below age-matched peers; progressive in severe forms | Types III, IV |
| Progressive hearing loss | Conductive, sensorineural, or mixed; typically begins in teens to 30s | Type I (up to 50% by age 50) |
| Joint hypermobility | Loose, overly flexible joints; flat feet; frequent dislocations | Types I, IV |
| Bone deformities | Bowing of long bones, scoliosis, barrel-shaped chest | Types III, IV |
| Easy bruising | Bruising out of proportion to injury due to fragile capillaries | All types |
How Signs Differ Across OI Types
OI was originally classified into four types by David Sillence in 1979. Genetic discoveries have since expanded that list well beyond 20 types, but the original four remain the clinical workhorses most doctors use.
Type I — Mild OI
This is the most common and mildest form. Fractures typically begin when a child starts walking and decrease after puberty. Blue sclera are almost always present. Stature is normal or near-normal. Many people with Type I aren’t diagnosed until adulthood, sometimes after a child is born with a more obvious case and the family is screened.
Type II — Perinatally Lethal
The most severe form. Infants are born with multiple fractures, severely underdeveloped lungs, and a soft calvarium (skull). Most cases are fatal within the first weeks to months of life, though rare survivors with intensive support have been reported. Fractures are often visible on prenatal ultrasound as early as 16–18 weeks gestation.
Type III — Severe, Progressive
Fractures are present at birth or occur very early in infancy. Progressive bone deformity is the defining feature — long bones bow, the spine curves, and the face takes on a triangular shape. Adults with Type III are often wheelchair-dependent and may be under 3 feet tall. Dentinogenesis imperfecta is common.
Type IV — Moderate
Falls between Types I and III in severity. Fractures are frequent in childhood but may improve after puberty. Sclera are typically normal or only faintly blue in childhood, which can delay diagnosis. Short stature is variable.
The Genetics Behind the Signs
About 85–90% of OI cases result from dominant mutations in COL1A1 or COL1A2 — the two genes encoding the alpha chains of type I collagen. Type I collagen is the primary structural protein in bone, skin, tendons, and the sclera of the eye. When these genes are defective, the collagen produced is either too little (quantitative defect, typically milder) or structurally abnormal (qualitative defect, typically more severe).
The remaining 10–15% of cases involve recessive mutations in genes like CRTAP, LEPRE1, PPIB, SERPINF1, and others — many discovered only in the last 15 years. These often produce moderate-to-severe phenotypes and are more common in consanguineous families.
About 25–35% of all OI cases arise from new (de novo) mutations with no family history. This is critical to know: a negative family history does not rule out OI.
How Osteogenesis Imperfecta Is Diagnosed
Diagnosis is primarily clinical, confirmed with genetic testing. Here’s the typical workup:
- Clinical evaluation: Fracture history, physical exam for scleral color, dental involvement, joint laxity, hearing, and skeletal deformity
- Family history: Three-generation pedigree looking for fractures, hearing loss, or short stature in relatives
- Genetic testing: Sequencing of COL1A1/COL1A2 first, then expanded panels if negative. Detects a causative mutation in >90% of cases
- DXA scan: Bone mineral density is typically low (Z-score ≤ −2.0), but a normal DXA does not exclude OI
- Skeletal survey (X-rays): Shows healed fractures, osteopenia, wormian bones in the skull, and long bone bowing
What OI Gets Confused With
The differential diagnosis matters enormously — especially in pediatric cases where child abuse is understandably considered when a child presents with unexplained fractures. Other conditions to rule out include Ehlers-Danlos syndrome (hypermobility overlap), juvenile osteoporosis, hypophosphatasia, and rickets. Genetic testing has become the definitive tiebreaker.
When to See a Doctor
Seek evaluation if you notice any of the following patterns:
- Two or more fractures before age 3 with no significant trauma
- A fracture from an activity that shouldn’t cause one (rolling over, gentle lifting)
- Blue or gray sclera combined with any fracture history
- Teeth that are translucent, chip easily, or are unusually discolored
- A family member with confirmed OI, even if your child seems unaffected
- Progressive hearing loss in a young adult with a history of childhood fractures
Start with your pediatrician or primary care doctor and request a referral to a geneticist or a center specializing in skeletal dysplasias. The OI Foundation maintains a directory of experienced clinics.
Frequently Asked Questions
Can you have osteogenesis imperfecta and not know it?
Yes — particularly with Type I. Some people are diagnosed in their 30s or 40s after years of being told they just have “weak bones” or early-onset osteoporosis. A history of 5+ fractures by adulthood, blue sclera, or hearing loss before age 50 should prompt genetic evaluation.
At what age do signs of OI usually appear?
It depends on severity. Type II is detectable on prenatal ultrasound. Type III presents at birth or in early infancy. Type I often becomes apparent when a child begins walking (12–18 months). Type IV may not be recognized until multiple fractures accumulate in childhood.
Can osteogenesis imperfecta be mistaken for child abuse?
This is a well-documented and deeply concerning scenario. Multiple unexplained fractures in an infant can trigger child protective investigations. If there’s any suspicion of OI — blue sclera, wormian bones on skull X-ray, family history — genetic testing should be pursued urgently. A 2016 study in Pediatrics emphasized that OI should be considered in the differential of any child with unexplained fractures.
Do people with OI have a normal life expectancy?
For Types I and IV, life expectancy is generally normal or near-normal with appropriate management. Type III is associated with reduced life expectancy due to respiratory complications from chest wall deformity. Type II is usually fatal in the perinatal period.
Is there a cure for osteogenesis imperfecta?
No cure exists yet, but treatment has improved dramatically. Bisphosphonates (like pamidronate and zoledronic acid) increase bone density and reduce fracture rates by 30–60% in children. Surgical rodding of long bones prevents and corrects deformity. Gene therapy and stem cell approaches are in early clinical trials.
